Research Topics
| Aimery de GramontSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)Isabelle Baumgaertner
Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
Clin Colorectal Cancer 9:E5-10. 2010..These analyses compare the safety and efficacy of 2 forms (levogyre [L] and dextro-levogyre [DL]) of leucovorin (LV) when used with 5-fluorouracil (5-FU) for the adjuvant treatment of patients with stage II and III colon cancer...
The evolving role of oxaliplatin in the management of colorectal cancerA de Gramont
Hopital Saint Antoine, Paris, France
Colorectal Dis 5:10-9. 2003..The first of these studies, MOSAIC, has already shown a very encouraging 23% decrease in the risk of relapse at 3 years (P = 0.002) with FOLFOX4 compared to LV5FU2...- Adjuvant therapy for stage II and III colorectal cancerAimery de Gramont
Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
Semin Oncol 34:S37-40. 2007..Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy... - Adjuvant therapy of stage II and III colon cancerAimery de Gramont
Hopital Saint Antoine, GERCOR, Paris, France
Semin Oncol 32:11-4. 2005..Ongoing important issues to be addressed relate to the optimal schedule and/or choice of chemotherapeutic regimens, and the efficacy of the combination of molecular agents with conventional chemotherapy... - Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancerAimery de Gramont
Hopital Saint Antoine, Paris, France
Oncology 69:46-56. 2005..001). Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy... - Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerA de Gramont
Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
J Clin Oncol 18:2938-47. 2000..This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point... - FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyChristophe Tournigand
Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
J Clin Oncol 22:229-37. 2004..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)... - Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancerMay Mabro
Department of Medical Oncology, , Paris, France
Am J Clin Oncol 26:254-8. 2003..FOLFIRI-2 achieved a good rate of response and stabilization in heavily pretreated patients despite significant toxicity... - Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independenAnne-Marie Coudray
INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
Int J Oncol 27:553-61. 2005..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers... - Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont
Hopital Saint Antoine, Paris Cedex 12, France
J Clin Oncol 25:3224-9. 2007.... - Pemetrexed in patients with gastrointestinal carcinomaAimery de Gramont
, , Paris, France
Semin Oncol 29:42-9. 2002.... - OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand
, Paris, France
J Clin Oncol 24:394-400. 2006..4% of these patients. CONCLUSION: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen. Further study is needed to fully evaluate oxaliplatin reintroduction... - Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialThierry Andre
Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
J Clin Oncol 27:3109-16. 2009..7% at 48 months. CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease... - Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 StudyBenoist Chibaudel
Hopital Saint Antoine, Paris Cedex 12, France
J Clin Oncol 27:5727-33. 2009.... - Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1Thierry Andre
Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
J Clin Oncol 25:3732-8. 2007.... - Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cellsEric Raymond
INSERM U482, Hopital Saint Antoine, Paris, France
Int J Oncol 21:361-7. 2002..These results argue in favor of clinical trials of chemotherapy combining MTA with oxaliplatin or irinotecan (CPT-11), for the treatment of patients with colon cancer... - [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer]Christophe Tournigand
Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12
Bull Cancer 93:S11-5. 2006..Combinations of capecitabine and oxaliplatine are also promising. The next step will come from the two new targeted therapies in metastatic colorectal cancer, directed against EGFR and VEGF... 
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont
Hopital Saint Antoine, Group Hospitalier Pitie Salpetriere, Paris, France
J Clin Oncol 28:460-5. 2010..New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association...- Colorectal cancer: integrating oxaliplatinChristophe Louvet
Service d Oncologie, Hopital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris, France
Curr Treat Options Oncol 4:405-11. 2003..The tolerance of the oxaliplatin/5-FU combination allows for design regimens integrating new drugs, such as biologic modifiers... - Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)Christophe Louvet
Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
Cancer Invest 21:14-20. 2003..Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma... - Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remissionChristophe Tournigand
Service d Oncologie Medicale, Hopital Saint Antoine, Paris, France
Gynecol Oncol 91:341-5. 2003.... - Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre
Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
J Clin Oncol 21:2896-903. 2003.... - [Colon cancer: what is new in 2004?]Thierry Andre
Service d Oncologie, Hopital Tenon, Paris, France
Bull Cancer 91:75-80. 2004..Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques (radiofrequency and cryotherapy) now allow to treat with curative intent metastases initially considered as non-resectable... - An overview of adjuvant systemic chemotherapy for colon cancerThierry Andre
Service d Oncologie, Hopital Tenon, Paris, France
Clin Colorectal Cancer 4:S22-8. 2004..Future studies in adjuvant therapy for colon cancer will explore oxaliplatin and 5-FU with or without antiangiogenesis or anti-epidermal growth factor agents... - Pemetrexed in advanced colorectal cancerChristophe Louvet
Hopital St Antoine, Service de Medecine Int Onc, Paris, France
Oncology (Williston Park) 18:56-62. 2004..All of these trials include vitamin supplementation. A phase III trial comparing the every-3-week pemetrexed/oxaliplatin regimen with FOLFOX4 as first-line treatment will be initiated if the outcome of the phase II trial is encouraging... - Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patientsFrédérique Maindrault-Goebel
Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
Eur J Cancer 41:2262-7. 2005..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence... - First-line therapy for advanced colorectal cancerAimery de Gramont
Service de médecine interne oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
Curr Oncol Rep 7:167-72. 2005..Furthermore, we fear that limited financial resources will also influence the management of this disease... - Targeted agents for adjuvant therapy of colon cancerAimery de Gramont
GERCOR Groupe Coopérateur Multidisciplinaire en Oncologie and Hôpital Saint Antoine, Paris, France
Semin Oncol 33:S42-5. 2006..Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial... - Stage II and stage III colon cancer: treatment advances and future directionsBenoit Rousseau
Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
Cancer J 16:202-9. 2010..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials... - Rapid evolution in colorectal cancer: therapy now and over the next five yearsAimery de Gramont
Hopital Saint Antoine, 184 Faubourg Saint Antoine, 75571 Paris Cedex 12, France
Oncologist 10:4-8. 2005..South San Francisco, CA, http://www.gene.com), and on the ability of applied genomics to distinguish between high- and low-risk populations... - Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factorsPierre Blanchard
Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
Gynecol Oncol 104:41-5. 2007..Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy...